Cantor Fitzgerald reiterates Trulieve Cannabis stock Overweight rating
Cantor Fitzgerald reiterated an Overweight rating and $15.00 price target on Trulieve Cannabis (TRLV), citing its scaled, vertically integrated medical operations. The stock is up 43% over six months, trading at $10.92. Q2 2026 earnings beat estimates with $0.11 EPS, though revenue slightly missed at $271M. The firm noted the company's organized, scalable platform and expects profitability this year.
How this was made
The 30-second read
Why it matters
The earnings beat and analyst reaffirmation could attract new buying, but revenue miss and regulatory headwinds temper enthusiasm.
Market read
The article provides fresh earnings data and analyst rating, offering a medium‑term trade idea for TRLV.
What to watch
Potential regulatory risk from the DEA's pause on cannabis rescheduling could affect future growth.
Background
Trulieve recently uplisted to the NYSE and completed a strategic restructuring. The DEA has paused cannabis rescheduling hearings, adding regulatory uncertainty.
Ticker impact
Cantor Fitzgerald reiterated an Overweight rating with a $15 price target and reported Trulieve's Q2 earnings beat expectations at $0.11 EPS versus $0.08 consensus.
likely upward pressure as the market prices in the earnings beat and higher target.
The combination of a fresh earnings beat and a maintained Overweight rating with a higher price target provides a clear catalyst for buying interest.
Market effects
Positive for the U.S. medical cannabis sector as the first NYSE‑listed cannabis company shows profitability.
May boost investor sentiment toward Florida‑based cannabis operators.
Limited to cannabis niche; no broad market impact.
Counterpoint
The earnings beat was modest and revenue missed; the stock may be overvalued relative to fair value.
Key entities
- companyTrulieve Cannabis Corp.
U.S. medical cannabis operator, ticker TRLV.
- analystCantor Fitzgerald
Equity research firm reiterating Overweight rating.
